Experienced in Emphysema

Richard N. Smit-Van Zyl

Division Of Pulmonology And University Of Cape Town Lung Institute, University Of Cape Town And Groote Schuur Hospital
Cape Town, WC, ZA 
Experienced in Emphysema
Division Of Pulmonology And University Of Cape Town Lung Institute, University Of Cape Town And Groote Schuur Hospital
Cape Town, WC, ZA 
OverviewLocationsClinical Research

Overview

Richard Smit-Van Zyl practices in Cape Town, South Africa. Mr. Smit-Van Zyl is rated as an Experienced expert by MediFind in the treatment of Emphysema. His top areas of expertise are Pulmonary Tuberculosis, Asthma, Chronic Obstructive Pulmonary Disease (COPD), and COVID-19.

His clinical research consists of co-authoring 84 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Emphysema.

Gender
Male

Locations

Division of Pulmonology and University of Cape Town Lung Institute, University of Cape Town and Groote Schuur Hospital
Cape Town, WC, South Africa
Other Locations
University Of Cape Town, Rondebosch, WC 7701, South Africa

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3

84 Total Publications

Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.
Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: November 05, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Smit-Van Zyl's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile